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ABSTRACT
INTRODUCTION: Serum glucose is commonly associated with a bad clinical prognosis in many diseases, 
including colorectal cancer (CRC). However, the real impact of glucose variation (GV) on the treatment and 
prognosis of CRC patients is unknown. Due to the absence of information, this study aimed to correlate GV 
and treatment response in advanced CRC. 
MATERIALS AND METHODS: Thirty-eight CRC patients with stage III and IV disease were studied. 
The selected ones were those who have had two consecutive computed-tomography scans and more than one 
serum glucose (SG) test between the CT scans, which left 19 people of the original group. 
RESULTS: The mean age of the 19 analyzed subjects was 58.6 years SD=18.26; CI 95% 50.9 – 71.0. Most of 
the patients were men (59%), with Wilt-Type KRAS mutation (63.2%), without metastasis (71%) and at a clin-
ical stage III (73.3%). No statistically significant value was found (p=0.126) between GV and treatment re-
sponse in advanced CRC patients. 
CONCLUSION: These findings cannot indicate a direct association between GV and treatment response in 
advanced CRC patient, but open space for evaluation of new methods of handling glucose variations in at-
tempt to get a better understanding about how glucose may influence the CRC prognosis.
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INTRODUCTION
Colorectal cancer (CRC) is linked to high mor-
bidity and mortality, mainly in the advanced stages 
(1). In Brazil, 2016, it is estimated that there were 16 
600 new cases for men and 17 620 for women (2). 
It is important to understand the influence of 
serum glucose (SG) in CRC tumorigenesis and its 
role in tumor cell behavior, cancer microenviron-
ment. It may be important for monitoring CRC pa-
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tients. When there are high levels of SG and pro-
longed use of insulin, the risk of developing CRC is 
increased (3-6). The intracellular glucose metabo-
lism has an important role in cellular proliferation 
and the increase of tumor size in CCR (7,8). 
The glucose variation (GV) as a relevant prog-
nosis factor in CRC patients is still little researched. 
However, SG is considered a risk predictor for biolog-
ical outcomes in patients in intensive care unit (ICU) 
(9,10) and in diabetes mellitus patients (11,12).
Therefore, this study aims to initiate a discus-
sion about the relation between SG variation and 
treatment response, as well as the methods to han-
dle the analysis of this variation in patients with ad-
vanced CRC. 
MATERIALS AND METHODS
Retrospective cohort study, in the period from 
January 2012 to July 2015 in the Oncológica do Brasil 
Hospital, in Belém, Pará. Clinical records of thirty-
eight individuals with colorectal cancer were stud-
ied. Out of them were excluded those who did not 
have: i) fasting SG test during the first CT scan ex-
amination; ii) at least two fasting SG tests between 
the first image examination and the subsequent one; 
iii) computed tomography scan (CT scan) after the 
diagnosis and subsequent CT scan. A total of 19 fit 
subjects remained in the study.
The glucose test was conducted in patients fast-
ing for at least 8 hours prior to the test. The results 
of the CT scan were obtained through an evaluation 
by a radiologist. The variation of the SG level was 
defined as all SG standard deviations (SD) for each 
patient. 
The treatment response (yes or no) was classi-
fied by radiological response (RECIST). Treatment 
response (yes) was defined as tumor size decrease or 
disease stabilization. Treatment response (no) was 
defined as increased tumor growth (increase >10% in 
tumor volume) and/or metastases.
Data were extracted in duplicate, and then an 
assessment of the data consistency was performed. 
The diagnosis of CRC was defined as the start of the 
study follow-up (t0) and the second image diagnos-
tics was at the end of study follow-up (t1) (Fig. 1). 
The study was approved by the Ethics Com-
mittee of the Faculty of Medicine of ABC, number 
1.173.508.
RESULTS
The mean age of the 19 analyzed subjects was 
58.6 years (SD=18.26; CI 95% 50.9 – 71.0). Table 1 
shows the epidemiological and clinical characteris-
tics of the individuals. The test’s power, calculated 
afterwards, was 50%. In addition to the sample, we 
used for this count the following parameters: mean 
of serum glucose levels and SD of serum glucose lev-
els as treatment response, using 5% alpha. 
The median follow-up time of subjects and time 
between the first and the second image diagnostics 
was 7.8 months (p25%-75%= 5.5 ; 18.7) and 5 months 
Fig. 1. A patient’s follow-up diagram. SG= serum glucose; 
CT-Scan: computed tomography scan
Characteristics N % CI-95%
Sex
   Male 13 59.10 0.39 ; 0.87
   Female 9 40.90 0.12 ; 0.60
KRAS Mutation
   Wilt-Type KRAS 12 63.20 0.39 ; 0.87
   KRAS Mutation 7 36.80 0.12 ; 0.60
Metastasis
   Peritoneal carcinomatosis 1 5.26 -0.05 ; 0.16
   Liver 2 10.52 -0.04 ; 0.25
   Bone 1 5.26 -0.57 ; 0.16
   Retroperitoneal 1 5.26 -0.57 ; 0.16
   Without metastasis 14 73.70 0.51 ; 0.95
Clinical staging
   III 14 73.70 0.51 ; 0.94
   IV 5 26.30 0.04 ; 0.48
Table 1. Epidemiological and clinical characteristics of 
subjects with colorectal cancer (Belém, 2015)
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(p25%-75%= 3.6 ; 8.0), respectively. The mean of 
number of glucose tests during the follow-up was 5.7 
(SD=2.2).
On analyzing the association between GV and 
treatment response (Fig. 2) no statistically significant 
value was found (p=0.126).
DISCUSSION
No studies were found on the relation between 
the GV and response to treatment in individuals 
with cancer. Despite that, the influence of glucose 
levels (13,14), insulin levels (6,13,15), presence of dia-
betes mellitus (16) and metabolic syndrome presence 
(5,17) are already related to the increased risk of CRC 
development (6,13,16) and impact the prognosis of 
those patients (5,14,16,17).
The mean age of the subjects analyzed (58.6 
years) was similar to what other authors have report-
ed (52.1 to 68 yeas) (6,18-20). Moreover, the propor-
tion of individuals identified with KRAS gene muta-
tion (36.8%) was also similar to the literature find-
ings (27% to 47%) (18-25), showing consistency with 
the results of previous studies.
GV is cited in studies as a risk factor for bio-
logical outcomes (11,12,26). ICU data showed a large 
variation of glucose (9,10) and blood pressure (27), 
which may have a negative impact on the patients’ 
prognosis. This raises a discussion about the varia-
tion, not in only glucose levels, interfering with bio-
logical outcomes. Thus, we began to think about the 
impact of methods of glucose measurement and how 
the follow-up fluctuations may be important for the 
CRC patients.
It is important to point out the great difficulty 
in establishing a consensus on the handling of glu-
cose variation. Several studies report the use of stan-
dard deviation as a main measure (9-11,28), but the 
coefficient of variation may also be used to measure 
it (9). The studies of heart rate variability are an ex-
ample of the diverse methods for evaluating a giv-
en biological factor (29). Thus, the establishment of 
a method of measurement with the corresponding 
patterns could be relevant in understanding the glu-
cose variations as a prognosis marker.
Sample size, the lack of a set time to follow up 
the individuals and the number of glucose tests may 
be highlighted as limiting factors of this research. 
However, the entry of new patients should increase 
the test’s power to confirm or refute the indicated re-
sults of this study. In addition, these points could be 
corrected as an effort to perform more sensible anal-
yses to assess the influence of follow-up time and 
the number of SG measurements in the proposed 
outcomes.
CONCLUSION
The reflection on new methods to assess the 
impact of metabolic factors is important for the un-
derstanding of the diverse influences of endogenous 
factors on the pathology prognosis. This study opens 
space for new debates that can encompass larger 
samples, control of other associated factors and eval-
uate new methods of handling glucose variations in 
attempt to achieve a better understanding about how 
glucose may influence the CRC prognosis.
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